Navigation Links
Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
Date:12/29/2008

CORONA, Calif., Dec. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP, 0.15 mg / 0.02 mg. Desogestrel/ethinyl estradiol and ethinyl estradiol tablets, USP, is the generic equivalent to Duramed Pharmaceuticals' Mircette(R) low-dose monthly oral contraceptive product, which is indicated for prevention of pregnancy.

Watson intends to launch the product in early January 2009 under the trade name Azurette(TM). For the 12-months ending September 2008, Mircette(R) had total U.S. sales of approximately $135 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by third parties; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

Mircette(R) is a registered trademark of Duramed Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
2. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
3. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
4. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
5. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
6. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
7. Watson Pharmaceuticals Reports Third Quarter 2008 Results
8. Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
9. Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds
10. Watson Wyatt Identifies Trends for Benefits Open Enrollment Season
11. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and athletics. It’s enough to overwork even the sharpest brain. , Power On, ... peak healthy activity without over clocking the brain. Each capsule contains Cognizin® Citicoline, ...
(Date:2/22/2017)... ... ... The National Academy of Certified Care Managers (NACCM) has ... period. NACCM, a nonprofit organization, has provided the premier certification for Care Managers ... to ensure that newly certified professionals are prepared to work effectively on behalf ...
(Date:2/22/2017)... ... February 22, 2017 , ... A ... smaller and sometimes harder to reach ones, according to the results of a ... Stroke Conference in Houston by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with ...
(Date:2/22/2017)... ... 2017 , ... The first-ever National Heart Valve Disease Awareness ... join together to increase recognition about the risks of heart valve disease (HVD) ... mark a nationwide movement to raise awareness about a disease that has not ...
(Date:2/22/2017)... Pittsburgh, PA (PRWEB) , ... February 22, 2017 , ... ... why some people seem to derive a heart-protective benefit from eating soy foods, while ... , Japanese men who are able to produce equol—a substance made by some ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), today announced its financial ... 31, 2016. ... This news release should be read in conjunction ... analysis for the years ended December 31, 2016 and 2015 ... www.sedar.com and on the Company,s website at ...
(Date:2/22/2017)... -- astic drugs develop from traditional single antineoplastic drug ... functions at multiple links. Research and development of antineoplastic ... Download the full report: https://www.reportbuyer.com/product/4696059/ ... of new tumors in China ... by industrialization and lifestyles changed by factors like urbanization, ...
(Date:2/22/2017)... 2017 Summary Provides understanding ... deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605673-summary/view-report.html Description The Global Congestive ... and access to partnering deals and agreements entered ... - Trends in partnering deals - ...
Breaking Medicine Technology: